The
post bariatric hypoglycemia treatment market consists of drugs and therapies
that provide treatment for post-bariatric hypoglycemia (PBH). PBH is a
condition characterized by abnormally low blood glucose levels after surgery
for weight loss, such as gastric bypass surgery or sleeve gastrectomy.
Post-bariatric hypoglycemia occurs due to improper glucose regulation after
alterations in anatomy as a result of bariatric surgery. Symptoms of PBH
include confusion, sweating, trembling, anxiety and fast heartbeat. The
increasing number of bariatric procedures along with growing awareness
regarding post-bariatric complications is a major factor driving demand for
effective post bariatric hypoglycemia treatment options.
The global Post-Bariatric
Hypoglycemia Market is estimated to be valued at US$ 265.5 Mn in 2024 and
is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the post bariatric hypoglycemia market are Vogenx,
Inc.,Eiger BioPharmaceuticals,Eli Lilly and Company,Novo Nordisk,Xeris
Pharmaceuticals. Vogenx, Inc. is developing an innovative gene therapy approach
for treating PBH while Eiger BioPharmaceuticals' peginterferon lambda is under
phase 2 trial.
The growing number of bariatric surgeries performed annually across the globe
is fueling the demand for effective post-surgical care and management of
associated complications like PBH. As per the International Federation for the
Surgery of Obesity and Metabolic Disorders, over 1.9 million bariatric
procedures were performed globally in 2020.
Technological advancements include development of gene therapies and novel
peptide therapeutics to restore normal glucose homeostasis in post-bariatric
surgery patients. Some companies are also developing bioelectronics therapies
and pancreas cell transplantation approaches for long term management of PBH.
Market Trends
Increasing research on novel drug targets - Several biotech companies are
conducting research to identify new drug targets and pathways involved in the
pathogenesis of PBH that can be modulated therapeutically. This includes
targets like somatostatin, amylin and others.
Focus on combination therapies - Given the complexity of metabolic
dysregulation post bariatric surgery, researchers are exploring efficacy of
combining different drug mechanisms and modalities into single regimens for
synergistic effects and optimal glycemic control.
Market Opportunities
Gene therapy - Gene therapy approaches aim to provide long term cure by
genetically modifying cells or tissues to restore normal functioning. Vogenx is
developing a gene therapy which can significantly reduce injection frequency.
Cell-based therapies - Transplantation of insulin secreting pancreatic islets
or stem cell derived beta cells can potentially provide robust glucose control.
This is a promising area of research with several clinical trials ongoing.
Impact of COVID-19 on Post Bariatric Hypoglycemia Market Growth and
Geographical Regions
The COVID-19 pandemic has significantly impacted the growth of the post
bariatric hypoglycemia market globally. During the initial months of the
pandemic, bariatric surgeries were postponed or cancelled as healthcare
resources were shifted to handle the rising number of COVID-19 cases.This led
to a decline in new patient volumes for post-bariatric hypoglycemia treatment.
However, existing patients continued treatment to manage their hypoglycemic
episodes. With easing of lockdowns and resumption of elective surgeries, the
market is witnessing a recovery in patient volumes.
Despite short term setbacks due to the pandemic, the long term outlook for the
post bariatric hypoglycemia market remains positive. The growing obesity rates
and increasing preference for bariatric surgeries are driving the patient pool
suffering from post-bariatric hypoglycemia. The market players are also
advancing the development of new drug formulations focused on subcutaneous
administration and protraction of action. This is expected to improve patient
adherence and clinical outcomes. Telemedicine and online consultations are also
being leveraged to ensure continuity of care during such crises. The market is
anticipated to surge past the pre-COVID forecasted revenues over the coming
years as healthcare systems strengthen their preparedness.
In terms of geographical contribution, North America dominates the post
bariatric hypoglycemia market in terms value. This is attributed to high
insurance coverage for obesity management treatments and growing public
awareness about post-bariatric complications in the region. Meanwhile, Asia
Pacific exhibits the fastest growth primarily due to improving accessibility to
bariatric procedures and economic development of major countries in the region.
Countries like China, Japan and India are expected to fuel the future expansion
of the post bariatric hypoglycemia market in Asia Pacific.
Get more insights on this topic : https://fortunetelleroracle.com/health-care/post-bariatric-hypoglycemia-market-treatment-is-in-trends-by-high-incidence-of-post-bariatric-surgery-complications-968921
What
Are The Key Data Covered In This Post-Bariatric Hypoglycemia
Market Report?
:- Market
CAGR throughout the predicted period
:- Comprehensive
information on the aspects that will drive the Post-Bariatric Hypoglycemia's
growth between 2024 and 2031.
:- Accurate
calculation of the size of the Post-Bariatric Hypoglycemia and its contribution
to the market, with emphasis on the parent market
:- Realistic
forecasts of future trends and changes in consumer behaviour
:- Post-Bariatric
Hypoglycemia Industry Growth in North America, APAC, Europe, South America, the
Middle East, and Africa
:- A
complete examination of the market's competitive landscape, as well as
extensive information on vendors
:- Detailed
examination of the factors that will impede the expansion of Post-Bariatric
Hypoglycemia vendors
About Author:
Ravina Pandya, Content Writer, has a strong foothold
in the market research industry. She specializes in writing well-researched
articles from different industries, including food and beverages, information
and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1.
Source: Coherent Market Insights, Public sources, Desk research
2.
We have leveraged AI tools to mine information and compile it
Comments
Post a Comment